Clay B. Siegall Buys 137,100 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall purchased 137,100 shares of the firm’s stock in a transaction on Wednesday, March 26th. The stock was acquired at an average price of $7.29 per share, for a total transaction of $999,459.00. Following the completion of the transaction, the chief executive officer now directly owns 806,736 shares of the company’s stock, valued at approximately $5,881,105.44. This trade represents a 20.47 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Immunome Price Performance

NASDAQ IMNM traded up $0.14 during trading hours on Wednesday, reaching $7.09. The company’s stock had a trading volume of 1,969,061 shares, compared to its average volume of 836,155. The company’s 50-day moving average is $9.67 and its two-hundred day moving average is $11.44. The firm has a market capitalization of $616.48 million, a price-to-earnings ratio of -0.87 and a beta of 1.93. Immunome, Inc. has a 1-year low of $6.94 and a 1-year high of $26.70.

Immunome (NASDAQ:IMNM) last posted its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The firm had revenue of $2.74 million during the quarter, compared to analyst estimates of $3.07 million. Equities analysts forecast that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on IMNM shares. Lifesci Capital assumed coverage on shares of Immunome in a report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 target price for the company. Stephens reaffirmed an “overweight” rating and issued a $30.00 price objective on shares of Immunome in a research note on Thursday, March 20th. Guggenheim reduced their price target on Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, March 20th. Finally, Wedbush reiterated an “outperform” rating and issued a $33.00 price target on shares of Immunome in a report on Thursday, March 20th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome presently has a consensus rating of “Buy” and a consensus price target of $25.50.

Institutional Investors Weigh In On Immunome

Hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its position in Immunome by 3.5% in the fourth quarter. Wellington Management Group LLP now owns 145,564 shares of the company’s stock valued at $1,546,000 after acquiring an additional 4,874 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Immunome by 5.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 41,505 shares of the company’s stock worth $441,000 after buying an additional 2,005 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Immunome by 32.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,193 shares of the company’s stock valued at $618,000 after purchasing an additional 14,328 shares in the last quarter. Woodline Partners LP raised its stake in shares of Immunome by 6.1% during the 4th quarter. Woodline Partners LP now owns 980,925 shares of the company’s stock worth $10,417,000 after buying an additional 56,533 shares during the last quarter. Finally, Two Sigma Advisers LP purchased a new stake in shares of Immunome in the fourth quarter valued at about $512,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.